Yinghan Chen

Yinghan Chen

Auto-generated profile, based on publicly available information

Yinghan Chen

State Key Laboratory of Coordination Chemistry, Jiangsu Key Laboratory of Advanced Organic Materials, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2023 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
WLWeipeng Li
Weipeng Li
YCYu Chen
Yu Chen
YCYinghan Chen
Yinghan Chen
SXSiyu Xia
Siyu Xia
WCWenju Chang
Wenju Chang
JXJin Xie
Jin Xie

30 May 2024 in JACS Au
Verified
Journal Article
Open access
HYHaojie Yang
Haojie Yang
HSHongbao Sun
Hongbao Sun
YCYinghan Chen
Yinghan Chen
YWYayue Wang
Yayue Wang
CYCheng Yang
Cheng Yang
HWhaoxing Wu
haoxing Wu
Despite the immense potential of tetrazine bioorthogonal chemistry in biomedical research, the in vivo performance of tetrazine probes is challenged by the inverse correlation between the physiological stability and reactivity of tetrazines. Additionally, the synthesis of functionalized tetrazines is often complex and requires specialized reagents. To overcome these issues, we present a novel tetrazine scaffold-triazolyl-tetrazine-that can be readily synthesized from shelf-stable ethynyl-tetrazines and azides. Triazolyl-tetrazines exhibit improved physiological stability along with high reactivity. We showcase the effectiveness of this approach by creating cell-permeable probes for protein labeling and live cell imaging, as well as efficiently producing 18F-labeled molecular probes for positron emission tomography imaging. By utilizing the readily available pool of functionalized azides, we envisage that this modular approach will provide universal accessibility to tetrazine bioorthogonal tools, facilitating applications in biomedicine and materials science.

18 June 2024 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
KZKaijin Zhang
Kaijin Zhang
JLJunyu Liu
Junyu Liu
YJYuqi Jiang
Yuqi Jiang
SSSimin Sun
Simin Sun
RWRongrong Wang
Rongrong Wang
Dehai LiDehai Li
Dehai Li

13 October 2017 in Advanced Synthesis & Catalysis
Verified
Journal Article
Closed access
PDF file
ZYZhi‐Hao You
Zhi‐Hao You
YCYing‐Han Chen
Ying‐Han Chen
XWXiao‐Na Wu
Xiao‐Na Wu
YLYankai Liu
Yankai Liu

1 March 2024 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
ZZZe Zhang
Ze Zhang
WWWanqing Wei
Wanqing Wei
SCSiqi Chen
Siqi Chen
JYJintao Yang
Jintao Yang
DSDongfan Song
Dongfan Song
HYHanyang Yu
Hanyang Yu

4 November 2017 in Marine Drugs
Verified
Journal Article
Open access
PDF file
FYFengli Yuan
Fengli Yuan
LQLiang Qiao
Liang Qiao
YCYinghan Chen
Yinghan Chen
XQXin Qi
Xin Qi
YLYankai Liu
Yankai Liu
MLMing Liu
Ming Liu
AS1041 is a novel synthesized anthraquinone lactone derivative of marine natural compound aspergiolide A (ASP-A) with new structure skeleton and marked cytotoxicity in cancer cells. To study its cytotoxicity in detail, we evaluated its activity on human K562 chronic myelogenous leukemia cells and investigated the related molecule mechanisms. AS1041 significantly inhibited the proliferation and colony formation of K562 cells. Moreover, AS1041 arrested cell cycle progression at G2/M phase in a concentration-dependent manner, and also caused concentration- and time-dependent induction of apoptosis. In addition, the molecular mechanisms investigation showed that AS1041 did not localize in the cellular nucleus and did not affect topoisomerases I or II. However, AS1041 could inactivate extracellular signal-regulated kinase (ERK) and contribute to AS1041-induced apoptosis. We concluded that AS1041 was cytotoxic to K562 leukemia cells and the cytotoxicity related to the cell cycle arrest, apoptosis induction, and ERK inhibition. These results implied that AS1041 was a novel derivative of ASP-A with significant cytotoxicity to chronic myelogenous leukemia cells and may have therapeutic potential for the treatment of cancer and leukemia.